# A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2)

> **NCT05836779** · PHASE2 · COMPLETED · sponsor: **Caliway Biopharmaceuticals Co., Ltd.** · enrollment: 23 (actual)

## Conditions studied

- Cellulite

## Interventions

- **DRUG:** CBL-514 injection

## Key facts

- **NCT ID:** NCT05836779
- **Lead sponsor:** Caliway Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-10
- **Primary completion:** 2023-11-29
- **Final completion:** 2024-01-05
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05836779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05836779, "A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05836779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*